Zum Hauptinhalt springen
xMedica

NCT07919678ClinicalTrials.gov

A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA 1)

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE-MONTHLY BEROBENATIDE IN ADULTS WITH KNEE OSTEOARTHRITIS AND OVERWEIGHT OR OBESITY (VESPER-OA 1)

RekrutiertNimmt laut Registereintrag derzeit Teilnehmende auf.
Diese Studie kontaktieren

Kurz gefasst

The purpose of this clinical study is to learn about the safety and effects of berobenatide (PF-08653944) for the treatment of knee osteoarthritis in adults with overweight or obesity. The study will last 52 weeks and compare the effects of…

Phase 3656 Teilnehmende gesucht40 Studienzentren2 Länder

Kategorien

In 1 Register registriert

Eine Studie kann in mehreren Registern registriert sein. Wir zeigen sie einmal und verlinken jeden Eintrag, den wir haben.

Die Studieninformationen werden so angezeigt, wie sie vom Register veröffentlicht wurden, in ihrer Originalsprache.

Interesse an dieser Studie?

Anmelden oder ein Konto erstellen um Ihr Interesse zu bekunden und diese Studie zu verfolgen.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Not stated: Registered after enrolment began (about 10 days after the recorded start)First posted 2026-11-05; recorded start 2026-10-26
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 635 other studies in this databaseCounted from the lead sponsor named in the record (Pfizer)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 3 conditions.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourDEFINITIVE

A definitive-grade design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm13/15

    Placebo / sham control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 40 sites

  • Data monitoring committee7/7

    A data monitoring committee is in place

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleMEDIUM

A medium-sized study, international in scope: 656 participants (target), run at 40 sites, across 2 countries.

How this score is built
  • Enrolment28/40

    656 participants (target)

  • Site count19/25

    40 sites

  • Country count7/15

    2 countries

  • Planned duration7/10

    Planned over about 24 months

  • Sponsor scale10/10

    Pfizer has led 630 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Zusammenfassung

The purpose of this clinical study is to learn about the safety and effects of berobenatide (PF-08653944) for the treatment of knee osteoarthritis in adults with overweight or obesity. The study will last 52 weeks and compare the effects of berobenatide compared to placebo on knee pain, physical function, and body weight. Study activities will include blood tests, knee pain assessment, physical function questionnaires and body measurements.

Erkrankungen

  • Obesity
  • Overweight
  • Osteoarthritis of the Knee

Eignung

Eignung
GeschlechtAlle
Alter18 Years – Kein Höchstalter
Gesunde FreiwilligeNein

Eignung im Wortlaut des Registers

Inclusion Criteria: * Adults 18 years of age or older, or the minimum age of consent according to local regulations. * Body mass index of at least 27 kg/m² at Screening. * Currently meets American College of Rheumatology (ACR) Criteria for knee OA. * Pain due to knee OA. * Knee radiograph consistent with knee osteoarthritis and Kellgren-Lawrence Grade 2 or 3. * Willingness to complete the required analgesic washout. * History of at least 1 self-reported unsuccessful dietary effort to lose body weight. Exclusion Criteria * Self-reported body weight increase or decrease greater than 5% within 90 days before Screening. * History of diabetes or Screening laboratory findings indicative of diabetes. * Known clinically significant gastric-emptying abnormality, history of acute or chronic pancreatitis, or active symptomatic gallbladder disease. * Personal history or first-degree family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. * Significant active or unstable psychiatric disorder. * Condition or knee disorder that could confound assessment of target-knee pain. * Prior target-knee replacement, planned target-knee replacement, or planned elective knee surgery during the study. * Recent use of weight-loss medication, any glucose-lowering therapy, or other protocol-prohibited treatment. * Prior participation in a berobenatide clinical trial with receipt of active treatment or placebo. * Hypersensitivity to a drug with glucagon-like peptide-1 receptor activity, including berobenatide, or any excipient.

Eignung in einfachen Aussagen

Die Kriterien dieses Eintrags wurden noch nicht in einzelne Aussagen aufgeschlüsselt. Der Registertext oben ist vollständig und ist die maßgebliche Fassung.

Studiendesign

Studiendesign
StudientypInterventionell
PhasePhase 3
ZuteilungRandomisiert
InterventionsmodellPARALLEL
Primäres ZielTREATMENT
VerblindungQUADRUPLE (4)
Teilnahme656 Teilnehmende gesucht

Sponsor und Mitwirkende

  • Pfizer Sponsor

Studienarme und Interventionen

  • PlaceboPLACEBO_COMPARATOR

    Participants will receive placebo as subcutaneous injection

  • Arm 1: Berobenatide Once MonthlyEXPERIMENTAL

    Participants will receive berobenatide by subcutaneous injection.

  • Arm 2: Berobenatide Once MonthlyEXPERIMENTAL

    Participants receive berobenatide by subcutaneous injection.

  • Arm 3: Berobenatide Once MonthlyEXPERIMENTAL

    Participants receive berobenatide by subcutaneous injection.

Interventionen

  • Arzneimittel Berobenatide

    Subcutaneous Injection

  • Sonstige Placebo

    Subcutaneous Injection

Endpunkte

  1. Primärer Endpunkt

    Change from baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale score

    Zeitrahmen Baseline and Week 52

  2. Sekundärer Endpunkt

    Percent change from baseline in Body Weight

    Zeitrahmen Baseline and Week 52

  3. Sekundärer Endpunkt

    Change From Baseline in High-Sensitivity C-Reactive Protein

    Zeitrahmen Baseline and Week 52

  4. Sekundärer Endpunkt

    Change from baseline in WOMAC Physical Function Subscale score

    Zeitrahmen Baseline and Week 52

  5. Sekundärer Endpunkt

    Percentage of participants with ≥50% reduction in the WOMAC pain subscale score

    Zeitrahmen Baseline and Week 52

  6. Sekundärer Endpunkt

    Percentage of participants with ≥30% reduction in the WOMAC pain subscale score

    Zeitrahmen Baseline and Week 52

  7. Sekundärer Endpunkt

    Proportion of participants with utilization of protocol specified pain medication during the washout period

    Zeitrahmen Baseline and Week 52

  8. Sekundärer Endpunkt

    Amount of protocol specified pain medication during the washout period

    Zeitrahmen Baseline and Week 52

  9. Sekundärer Endpunkt

    Change from baseline in WOMAC stiffness score

    Zeitrahmen Baseline and Week 52

  10. Sekundärer Endpunkt

    Change from baseline in WOMAC total score

    Zeitrahmen Baseline and Week 52

  11. Sekundärer Endpunkt

    Proportion of participants achieving ≥50% reduction in the WOMAC physical function subscale score

    Zeitrahmen Baseline and Week 52

  12. Sekundärer Endpunkt

    Proportion of participants meeting OMERACT-OARSI

    Zeitrahmen Baseline and Week 52

  13. Sekundärer Endpunkt

    Change from baseline in Average Pain Intensity-Numerical Rating Score

    Zeitrahmen Baseline and Week 52

  14. Sekundärer Endpunkt

    Change from baseline in Worst Pain Intensity -Numerical Rating Score

    Zeitrahmen Baseline and Week 52

  15. Sekundärer Endpunkt

    Change from baseline in SF-36 domain scales and component summary scales

    Zeitrahmen Baseline and Week 52

  16. Sekundärer Endpunkt

    Change from baseline in Body Weight

    Zeitrahmen Baseline and Week 52

  17. Sekundärer Endpunkt

    Change from Baseline in Body Mass Index

    Zeitrahmen Baseline and Week 52

  18. Sekundärer Endpunkt

    Number of participants with Treatment Emergent Adverse Events (TEAEs)

    Zeitrahmen Baseline and Week 52

  19. Sekundärer Endpunkt

    Number of Participants with Serious Adverse Events (SAE)

    Zeitrahmen Baseline and Week 52

  20. Sekundärer Endpunkt

    Number of Participants with AE leading to permanent discontinuation from study intervention or study

    Zeitrahmen Baseline and Week 52

  21. Sekundärer Endpunkt

    Number of Participants with Adverse Events of Special Interest (AESI)

    Zeitrahmen Baseline and Week 52

  22. Sekundärer Endpunkt

    Number of Participants with Clinical laboratory abnormalities

    Zeitrahmen Baseline and Week 52

  23. Sekundärer Endpunkt

    Change from baseline in timed walking distance at Week 52

    Zeitrahmen Baseline and Week 52

  24. Sekundärer Endpunkt

    Percentage of Participants Reporting Improvement in Patient Global Impression of Severity (PGI-S) for knee-OA related physical function

    Zeitrahmen Baseline and Week 52

  25. Sekundärer Endpunkt

    Percentage of Participants Reporting Improvement in Patient Global Impression of Severity (PGI-S) for knee-OA pain

    Zeitrahmen Baseline and Week 52

  26. Sekundärer Endpunkt

    Percentage of Participants Reporting Improvement in Patient Global Impression of Change (PGI-C) for knee-OA related physical function

    Zeitrahmen Baseline and Week 52

  27. Sekundärer Endpunkt

    Percentage of Participants Reporting Improvement in Patient Global Impression of Change PGI-C for knee-OA pain

    Zeitrahmen Baseline and Week 52

  28. Sekundärer Endpunkt

    Change From Baseline in EuroQol 5-Dimension, 5-Level (EQ-5D-5L) Index Score

    Zeitrahmen Baseline and Week 52

  29. Sekundärer Endpunkt

    Change From Baseline in EuroQol-visual analog scale (EQ-VAS) Score

    Zeitrahmen Baseline and Week 52

  30. Sekundärer Endpunkt

    Change From Baseline in Work Productivity and Activity Impairment - General Health (WPAI:GH) Absenteeism Score

    Zeitrahmen Baseline and Week 52

  31. Sekundärer Endpunkt

    Change From Baseline in WPAI:GH Work productivity loss score

    Zeitrahmen Baseline and Week 52

  32. Sekundärer Endpunkt

    Change From Baseline in WPAI:GH Activity impairment score

    Zeitrahmen Baseline and Week 52

  33. Sekundärer Endpunkt

    Change From Baseline in Systolic Blood Pressure (SBP)

    Zeitrahmen Baseline and Week 52

  34. Sekundärer Endpunkt

    Change From Baseline in Diastolic Blood Pressure (DBP)

    Zeitrahmen Baseline and Week 52

  35. Sekundärer Endpunkt

    Change From Baseline in Total Cholesterol

    Zeitrahmen Baseline and Week 52

  36. Sekundärer Endpunkt

    Change From Baseline in High-density lipoprotein cholesterol (HDL-C)

    Zeitrahmen Baseline and Week 52

  37. Sekundärer Endpunkt

    Change From Baseline in Low-density lipoprotein cholesterol (LDL-C)

    Zeitrahmen Baseline and Week 52

  38. Sekundärer Endpunkt

    Change from baseline in Non-HDL Cholesterol

    Zeitrahmen Baseline and Week 52

  39. Sekundärer Endpunkt

    Change from baseline in Very low-density lipoprotein cholesterol (VLDL) Cholesterol

    Zeitrahmen Baseline and Week 52

  40. Sekundärer Endpunkt

    Change from baseline in Triglycerides

    Zeitrahmen Baseline and Week 52

Daten

Daten
Startdatum26. Oktober 2026 (tatsächlich)
Primärer Abschluss22. August 2028 (geschätzt)
Abschluss10. Oktober 2028 (geschätzt)
Erstveröffentlichung5. November 2026 (tatsächlich)
Zuletzt aktualisiert5. November 2026
Ergebnisse veröffentlichtIm Registereintrag nicht angegeben
Status zuletzt bestätigtOktober 2026

Tatsächlich bedeutet, dass das Ereignis eingetreten ist. Geschätzt bedeutet, dass der Sponsor es erwartet. Die beiden bedeuten Unterschiedliches.

Standorte

7 Studienzentren rekrutieren

Canada

Canada
EinrichtungStadtBundesland oder RegionStatus
Bluewater Clinical Research Group Inc.SarniaOntarioRekrutierung noch nicht begonnen

United States

United States
EinrichtungStadtBundesland oder RegionStatus
Albuquerque Clinical Trials, Inc.AlbuquerqueNew MexicoRekrutierung noch nicht begonnen
Charlottesville Medical Research Center, LLCCharlottesvilleVirginiaRekrutierung noch nicht begonnen
Northwestern University Feinberg School Of MedicineChicagoIllinoisRekrutierung noch nicht begonnen
Great Lakes Clinical Trials, LLC dba Flourish ResearchChicagoIllinoisRekrutierung noch nicht begonnen
Northwestern MedicineChicagoIllinoisRekrutierung noch nicht begonnen
Northwestern Memorial Hospital, Diagnostic Testing Center (Phlebotomy/EKG)ChicagoIllinoisRekrutierung noch nicht begonnen
Northwestern Memorial Hospital, Investigational Drug ServiceChicagoIllinoisRekrutierung noch nicht begonnen
Clinical Research of West Florida, Inc.ClearwaterFloridaRekrutierung noch nicht begonnen
Skylight Health ResearchColorado SpringsColoradoRekrutierung noch nicht begonnen
Mercy Family ClinicDallasTexasRekrutierung noch nicht begonnen
Universal Axon Clinical Research LLCDoralFloridaRekrutiert
Altoona Center For Clinical ResearchDuncansvillePennsylvaniaRekrutiert
Headlands Research California, LLCEscondidoCaliforniaRekrutierung noch nicht begonnen
Profound Research LLCFarmington HillsMichiganRekrutiert
Cedar Health ResearchFort WorthTexasRekrutierung noch nicht begonnen
Novant Health Granite Quarry Internal Medicine (knee x-ray)Granite QuarryNorth CarolinaRekrutierung noch nicht begonnen
BRCR Global LouisianaGretnaLouisianaRekrutierung noch nicht begonnen
JCCT-JUNO NW HoustonHoustonTexasRekrutierung noch nicht begonnen
Westside Center for Clinical ResearchJacksonvilleFloridaRekrutierung noch nicht begonnen
Activian Clinical ResearchKingwoodTexasRekrutierung noch nicht begonnen
Renstar Medical ResearchLady LakeFloridaRekrutierung noch nicht begonnen
Monroe Biomedical ResearchMonroeNorth CarolinaRekrutiert
AMR ClinicalNormanOklahomaRekrutierung noch nicht begonnen
Renstar Medical ResearchOcalaFloridaRekrutierung noch nicht begonnen
Prospective Research Innovations Inc.Rancho CucamongaCaliforniaRekrutierung noch nicht begonnen
Accellacare - SalisburySalisburyNorth CarolinaRekrutierung noch nicht begonnen
Consano Clinical Research, LLCShavano ParkTexasRekrutierung noch nicht begonnen
Revive Research Institute, Inc.Sterling HeightsMichiganRekrutiert
Clinical Research AtlantaStockbridgeGeorgiaRekrutierung noch nicht begonnen
Clinical Research of West Florida, Inc.TampaFloridaRekrutierung noch nicht begonnen
AMR ClinicalTempeArizonaRekrutierung noch nicht begonnen
DM Clinical ResearchTomballTexasRekrutierung noch nicht begonnen
Solace Clinical ResearchTustinCaliforniaRekrutierung noch nicht begonnen
Velocity Clinical Research, WacoWacoTexasRekrutierung noch nicht begonnen
Elevate Clinical ResearchWichitaKansasRekrutierung noch nicht begonnen
Delaney RadiologistWilmingtonNorth CarolinaRekrutiert
AccellacareWilmingtonNorth CarolinaRekrutiert
North Georgia Internal MedicineWoodstockGeorgiaRekrutierung noch nicht begonnen
North Georgia Clinical Research, LLCWoodstockGeorgiaRekrutierung noch nicht begonnen

Studiendokumente

In diesem Registereintrag sind keine Dokumente verlinkt.

Änderungen im Zeitverlauf

Seit wir diesen Eintrag erstmals eingelesen haben, wurden keine Änderungen erfasst.

Eine Änderung wird jedes Mal erfasst, wenn der Sponsor den Registereintrag aktualisiert. Status, Daten, Teilnahme und Studienzentren erscheinen hier, sobald sie sich ändern.